Federal contract award

75N93020C00048

TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeNATIONAL INSTITUTES OF HEALTH NIAID
NAICS541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSCAN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeCOST PLUS FIXED FEE
Obligations$11.5M
Current contract value$11.5M
Potential contract value / ceiling$25.6M
Start dateSep 1, 2020
Current end dateMar 31, 2027
Potential end dateMar 31, 2027
Latest award activityMar 31, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 19 of 19 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Mar 31, 2026P00018$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Dec 31, 2025P00017$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Sep 30, 2025P00016$721.6KTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Sep 23, 2025P00015$-2.6KTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
May 23, 2025P00014$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Mar 14, 2025P00013$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Mar 13, 2025P00012$4.0MTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Sep 12, 2024P00011$198.3KTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Jun 20, 2024P00010$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Jun 3, 2024P00009$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Oct 31, 2023P00008$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Jun 29, 2023P00007$3.5MTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Apr 12, 2023P00006$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Sep 29, 2022P00005$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Apr 6, 2022P00004$1.6MTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Aug 27, 2021P00003$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Aug 13, 2021P00002$1.2MTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Apr 26, 2021P00001$0TO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.
Aug 27, 20200$215.1KTO ADVANCE THE DEVELOPMENT OF THE SHIGETEC VACCINE THROUGH CGMP MANUFACTURING AND RELEASE OF ADDITIONAL CGMP LOTS FOR USE IN A SERIES OF PHASE 2 CLINICAL TRIALS.

Estimated positioning window

Nov 1, 2026 – Jan 30, 2027

Recompete signal:
80/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 80/100. Available recorded signals: 75 points.

Contract end 2027-03-31 (150 days from calculation)
+35 points
155 historical awards in this buyer and category group
+15 points
19 recorded award transactions
+10 points
Latest award action: 2026-03-31
+5 points
Parent award identifier recorded
+0 points
Solicitation identifier recorded
+10 points
Linked official forecast
+0 points
Calculated on
2026-11-01 10:17:53.997580+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Nov 1, 2026.

Research next steps

  1. Check the linked forecast or SAM for a confirmed solicitation and current timing.
  2. Check the stated set-aside against the solicitation and current certifications.
  3. Review the award scope and buyer evidence before making a bid/no-bid decision.